文献速递炎症性肠病

老年炎症性肠病患者衰弱患病率因评估量表而异

The Prevalence of Frailty in Elderly Inflammatory Bowel Disease Patients Varies Depending on the Scale Used.
PubMed 文献 · Aliment Pharmacol Ther · 2026-07-31

BACKGROUND: Frailty is an important predictor of adverse outcomes in inflammatory bowel diseases (IBD); however, it has not been established which is the best way to measure frailty in IBD patients.…

要点

  • 老年IBD患者衰弱患病率因量表不同差异大(4.4%–16.8%)。
  • 四种衰弱量表间一致性较低(Fleiss Kappa 0.25)。
  • 多重用药和CIRS-G≥3与衰弱风险独立相关。

核心结论

  • 老年IBD患者衰弱患病率因所用评估量表不同而异。
  • 多重用药和CIRS-G≥3与衰弱风险升高相关,且不受评估工具影响。

研究设计与样本

  • 比较Fried衰弱表型(FFP)、FRAIL量表、临床衰弱评分(CFS)和SHARE-FI四种衰弱量表。
  • 收集临床人口学数据及合并症指数(Charlson和CIRS-G),评估量表间一致性并采用logistic回归分析衰弱相关因素。

主要发现

  • 衰弱患病率:FRAIL 4.4%,CFS 4.6%,SHARE-FI 12.4%,FFP 16.8%。
  • 四种量表间一致性为Fleiss Kappa 0.25。
  • 多因素分析中,四种量表均显示衰弱与多重用药和CIRS-G≥3独立相关。
  • 三种量表显示较高年龄、女性、家庭支持差、IBD病程和临床IBD活动与较高衰弱风险统计相关。

临床怎么用

  • 老年IBD患者衰弱评估应意识到量表选择影响患病率估计。
  • 对多重用药或CIRS-G≥3的老年IBD患者应关注衰弱风险。

局限性

  • 需要进一步前瞻性研究明确衰弱对老年IBD患者的影响并改进治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is an important predictor of adverse outcomes in inflammatory bowel diseases (IBD); however, it has not been established which is the best way to measure frailty in IBD patients. AIM: To compare four frailty scales in elderly IBD patients and identify factors associated with this condition. METHODS: Multicentre cohort study in IBD outpatients ≥ 60 years old using four frailty scales: Fried Frailty Phenotype (FFP), FRAIL scale, Clinical Frailty Score (CFS) and SHARE-FI. Clinical-demographic data and comorbidity indices (Charlson and CIRS-G) were obtained. The agreement between scales was evaluated, and logistic regression analysis was conducted to assess the factors associated with frailty. RESULTS: Six hundred and twelve patients (56.4% Crohn's disease) were enrolled from March to June 2024. Prevalence of frailty varied from 4.4% (FRAIL), 4.6% (CFS), 12.4% (SHARE-FI) up to 16.8% (FFP). The agreement between all the scales used was Fleiss' Kappa 0.25. Frailty was independently associated with polypharmacy and CIRS-G ≥ 3 on multivariate analysis of the four scales. Other factors, such as higher age, female gender, poor family support, disease duration of IBD, and clinical IBD activity were statistically associated with higher risk of frailty according to three of the four scales used. CONCLUSIONS: The prevalence of frailty in elderly IBD patients varies depending on the scale used. Polypharmacy and CIRS-G ≥ 3 are associated with a higher risk of frailty, regardless of the frailty assessment tool used. Further prospective studies are needed to identify the impact of frailty in elderly IBD patients and improve treatment strategies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Carballo-Folgoso L, Alcorta JMD, Varela P, et al. The Prevalence of Frailty in Elderly Inflammatory Bowel Disease Patients Varies Depending on the Scale Used. Aliment Pharmacol Ther. 2026. PMID: 42535580. doi:10.1111/apt.70895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。